Genetically modified Bifidobacterium displaying Salmonella -antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model

• Published in: Vaccine 2010-09, Vol.28 (41), p.6684-6691
• Main Authors: Yamamoto, Sakura, Wada, Jun, Katayama, Takane, Jikimoto, Takumi, Nakamura, Masakuni, Kinoshita, Shohiro, Lee, Kyung-Mi, Kawabata, Masato, Shirakawa, Toshiro
• Format: Article
• Language: English
• Subjects: Allergy and Immunology; Animal models; Animals; Antibodies, Bacterial - immunology; Antigens, Bacterial - immunology; Applied microbiology; Bacteriology; Bifidobacterium; Bifidobacterium - immunology; Bifidobacterium longum; Biological and medical sciences; Cell surface; Colony-forming cells; Data processing; Disease Models, Animal; Female; Flagellin - immunology; Fundamental and applied biological sciences. Psychology; Immune system; Immunity, Mucosal; Immunization; Infections; Mice; Mice, Inbred BALB C; Microbiology; Miscellaneous; Mortality; Mucosal immunity; Mucosal vaccine; Oral administration; Recombinant Fusion Proteins - immunology; Salmonella; Salmonella typhimurium; Salmonella typhimurium - immunology; Survival; Typhoid; Typhoid fever; Typhoid Fever - immunology; Typhoid Fever - prevention & control; Typhoid-Paratyphoid Vaccines - immunology; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Waterborne diseases
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2010.08.007

Abstract We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella -flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5 × 107 CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum , or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0 × 107 CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity.